Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes.

Lo, Chris Wai Hang; Fei, Yue; Cheung, Bernard Man Yung

Lo, Chris Wai Hang; Fei, Yue; Cheung, Bernard Man Yung.

Afiliação

Lo CWH; Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong Pokfulam, Hong Kong, China.
Fei Y; Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong Pokfulam, Hong Kong, China.
Cheung BMY; Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong Pokfulam, Hong Kong, China.

Card Fail Rev ; 7: e04, 2021 Mar.

Article em En | MEDLINE | ID: mdl-33747548

Palavras-chave

Antidiabetic drug; cardiovascular outcome; dipeptidyl peptidase-4 inhibitor; glucagon-like peptide 1 receptor agonist; heart failure; mortality; renal outcomes; sodiumglucose co-transporter 2 inhibitor; stroke; type 2 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article